Table 1.
Comparison between training cohort and validation cohort of clinicopathological characteristics of involved colon cancer patients.
| LCC | RCC | |||||
|---|---|---|---|---|---|---|
| Training cohort (n=121) | Validation cohort (n=64) | P | Training cohort (n=121) | Validation cohort (n=64) | P | |
| Age (years), means±SD | 61.16±12.369 | 60.422±11.759 | 0.696 | 61.61±13.291 | 60.969±12.786 | 0.752 |
| Sex, n (%) | 0.546 | 0.347 | ||||
| Male | 81 (66.9%) | 40 (62.4%) | 91 (75.2%) | 44 (68.8%) | ||
| Female | 40 (33.1%) | 24 (37.6%) | 30 (24.8%) | 20 (31.2%) | ||
| Tumor size, n (%) | 0.845 | 0.421 | ||||
| <5 cm | 83 (68.6%) | 43 (67.2%) | 68 (56.2%) | 32 (50.0%) | ||
| ≥5 cm | 38 (31.4%) | 21 (32.8%) | 53 (43.8%) | 32 (50.0%) | ||
| Tumor differentiation, n (%) | 0.169 | 0.803 | ||||
| Well | 24 (19.8%) | 3 (4.6%) | 12 (9.9%) | 7 (11.0%) | ||
| Moderate | 63 (52.1%) | 43 (67.2%) | 85 (70.2%) | 45 (70.2%) | ||
| Poor | 34 (28.1%) | 18 (28.2%) | 24 (19.8%) | 12 (18.8%) | ||
| DNA mismatch repair, n (%) | 0.654 | 0.847 | ||||
| dMMR | 16 (13.2%) | 7 (10.9%) | 25 (20.7%) | 14 (21.9%) | ||
| pMMR | 105 (86.8%) | 57 (89.1%) | 96 (79.3%) | 50 (78.1%) | ||
| T stage, n (%) | 0.972 | 0.559 | ||||
| T1 | 9 (7.4%) | 8 (12.4%) | 11 (9.1%) | 7 (11.0%) | ||
| T2 | 20 (16.5%) | 10 (15.6%) | 23 (19.0%) | 15 (23.4%) | ||
| T3 | 73 (60.3%) | 32 (50.0%) | 69 (57.0%) | 32 (50.0%) | ||
| T4 | 19 (15.7%) | 14 (21.8%) | 18 (14.9%) | 10 (15.6%) | ||
| N stage, n (%) | 0.949 | 0.511 | ||||
| N0 | 37 (30.6%) | 22 (34.4%) | 55 (45.5%) | 34 (53.1%) | ||
| N1 | 52 (43.0%) | 22 (34.4%) | 41 (33.9%) | 16 (25.0%) | ||
| N2 | 32 (26.4%) | 20 (31.3%) | 25 (20.7%) | 14 (21.9%) | ||
| AJCC stage, n (%) | 0.316 | 0.687 | ||||
| I | 21 (17.4%) | 10 (15.6%) | 27 (22.3%) | 14 (21.8%) | ||
| II | 31 (25.6%) | 12 (18.8%) | 45 (37.2%) | 18 (28.2%) | ||
| III | 69 (57.0%) | 42 (65.6%) | 49 (40.5%) | 32 (50.0%) | ||
| Venous invasion, n (%) | 0.569 | 0.936 | ||||
| Negative | 88 (72.7%) | 44 (68.8%) | 92 (76.0%) | 49 (76.6%) | ||
| Positive | 33 (27.3%) | 20 (31.2%) | 29 (24.0%) | 15 (23.4%) | ||
| Perineural Invasion, n (%) | 0.228 | 0.729 | ||||
| Negative | 79 (65.3%) | 36 (56.2%) | 75 (62.0%) | 38 (59.4%) | ||
| Positive | 42 (34.7%) | 28 (43.8%) | 46 (38.0%) | 26 (40.6%) | ||
| Tumor budding, n (%) | 0.466 | 0.920 | ||||
| Negative | 23 (19.0%) | 9 (14.1%) | 15 (12.4%) | 8 (12.5%) | ||
| Weak | 57 (47.1%) | 31 (48.4%) | 73 (60.3%) | 38 (59.4%) | ||
| Moderate | 27 (22.3%) | 16 (25.0%) | 28 (23.1%) | 15 (23.4%) | ||
| Strong | 14 (11.6%) | 8 (12.5%) | 5 (4.1%) | 3 (4.7%) | ||
LCC Left-side colon cancer, RCC Right-side colon cancer, dMMR Deficient mismatch repair, pMMR Proficient mismatch repair.